Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma

Some patients with diffuse large B-cell lymphoma (DLBCL) present with a concurrent indolent lymphoma at diagnosis. Their outcomes in the rituximab era are not fully defined. Using a prospectively followed cohort of 1324 newly diagnosed DLBCL patients treated with immunochemotherapy, we defined the p...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Blood
Autores principales: Wang, Yucai, Link, Brian K., Witzig, Thomas E., Maurer, Matthew J., Allmer, Cristine, King, Rebecca L., Feldman, Andrew L., Habermann, Thomas M., Ansell, Stephen M., Slager, Susan L., Cerhan, James R., Nowakowski, Grzegorz S.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2019
Materias:
Clinical Trials and Observations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6888139/
https://ncbi.nlm.nih.gov/pubmed/31350266
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019000858
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares